Petros Pharmaceuticals (PTPI) Analyst Estimates Annual - Discounting Cash Flows
Petros Pharmaceuticals, Inc.
PTPI (NASDAQ)

* (except for per share items) of USD
Period Ending: 2028
12-31
2027
12-31
2026
12-31
2025
12-31
2024
12-31
2023
12-31
Number of Analysts 1 1 1 1 1 1
Estimated Revenue
Low 27.8 20.6 11.0 5.48 5.43 7.70
Average 27.8 20.6 11.0 5.48 5.43 7.70
High 27.8 20.6 11.0 5.48 5.43 7.70
Estimated EBITDA
Low -21.3 -15.8 -8.45 -4.20 -4.16 -5.90
Average -21.3 -15.8 -8.45 -4.20 -4.16 -5.90
High -21.3 -15.8 -8.45 -4.20 -4.16 -5.90
Estimated EBIT
Low -27.8 -20.6 -11.0 -5.48 -5.43 -7.70
Average -27.8 -20.6 -11.0 -5.48 -5.43 -7.70
High -27.8 -20.6 -11.0 -5.48 -5.43 -7.70
Estimated Net Income
Low 0.74 -1.52 -2.39 -2.37 -4.63 -11.2
Average 0.74 -1.52 -2.39 -2.37 -4.63 -11.2
High 0.74 -1.52 -2.39 -2.37 -4.63 -11.2
Estimated SGA Expenses
Low 47.4 35.2 18.8 9.34 9.27 13.1
Average 47.4 35.2 18.8 9.34 9.27 13.1
High 47.4 35.2 18.8 9.34 9.27 13.1
Estimated EPS
Low 0.340 -0.700 -1.100 -1.090 -2.130 -5.150
Average 0.340 -0.700 -1.100 -1.090 -2.130 -5.150
High 0.340 -0.700 -1.100 -1.090 -2.130 -5.150
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us